Purple Biotech Closes $2.8M ADS Offering
Ticker: PPBT · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1614744
Sentiment: bullish
Topics: offering, financing, biotech
TL;DR
Purple Biotech just closed a $2.8M ADS offering, bringing in cash for the company.
AI Summary
On December 5, 2024, Purple Biotech Ltd. announced the closing of a registered direct offering, successfully raising $2.8 million through the sale of American Depositary Shares. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel.
Why It Matters
This capital raise provides Purple Biotech with additional funds, potentially enabling them to advance their drug development pipeline or pursue other strategic initiatives.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical sector, which is inherently risky due to drug development timelines, regulatory hurdles, and market competition.
Key Numbers
- $2.8M — Capital Raised (Funds secured from the registered direct offering of American Depositary Shares.)
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer and issuer of the offering
- $2.8 million (dollar_amount) — Amount raised in the registered direct offering
- December 5, 2024 (date) — Date of the press release announcing the offering closing
- Kitov Pharma Ltd. (company) — Former name of Purple Biotech Ltd.
FAQ
What was the total amount raised in the registered direct offering?
Purple Biotech Ltd. announced the closing of a registered direct offering that raised $2.8 million.
When was the press release announcing the closing of the offering issued?
The press release was issued on December 5, 2024.
What type of securities were offered in the direct offering?
The offering involved American Depositary Shares.
What is Purple Biotech Ltd.'s former name?
Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd.
Where is Purple Biotech Ltd. located?
Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot, Israel.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-12-05 07:21:45
Key Financial Figures
- $2.8 Million — uo; Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American
Filing Documents
- ea0223739-6k_purplebio.htm (6-K) — 14KB
- ea022373901ex99-1_purplebio.htm (EX-99.1) — 13KB
- 0001213900-24-105775.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. December 5, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2